In a natural context, membrane fusion mediated by the human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins involves both the exterior envelope glycoprotein (gpl20) and the transmembrane glycoprotein (gp4l). Perez et al. (J. Virol. 66:4134-4143, 1992) reported that a mutant HIV-1 envelope glycoprotein containing only the signal peptide and carboxyl terminus of the gpl20 exterior glycoprotein fused to the complete gp4l glycoprotein was properly cleaved and that the resultant gp4l glycoprotein was able to induce the fusion of even CD4-negative cells. In the studies reported herein, mutant proteins identical or similar to those studied by Perez et al. lacked detectable cell fusion activity. The proteolytic processing of these proteins was very inefficient, and one processed product identified by Perez et al. as the authentic gp4l glycoprotein was shown to contain carboxyl-terminal gpl20 sequences. Furthermore, no fusion activity was observed for gp4l glycoproteins exposed after shedding of the gpl20 glycoprotein by soluble CD4. Thus, evidence supporting a gpl20-independent cell fusion activity for the HIV-1 gp41 glycoprotein is currently lacking.
The envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1), the etiologic agent of AIDS, mediate virus entry and cytopathic effects (2, 29, 38, 52, 55, 57) . The gpl60 envelope glycoprotein precursor is synthesized in the endoplasmic reticulum and is subsequently cleaved in a late Golgi compartment to yield the exterior envelope glycoprotein (gp120) and the transmembrane glycoprotein (gp4l) (17, 18, 58, 62, 65) . Recently furin, a subtilisin-like endoprotease, has been shown to cleave the HIV-1 gpl60 glycoprotein in HeLa cells and in T-lymphocytic cell lines (27) . Following cleavage, the gpl20 glycoprotein remains anchored to the cellular or viral membrane through noncovalent bonds to the gp4l glycoprotein (30, 34a, 36) .
HIV-1 entry and cytopathic effects involve the envelope glycoprotein-mediated fusion of virus-cell and cell-cell membranes, respectively. The initial event in these processes is the binding of the gpl20 glycoprotein to the CD4 receptor (13, 35, 39, 41, 42) . The CD4 binding region of gpl20 consists of discontinuous sequences located in the third and fourth conserved regions (11, 12, 37, 46) . Mutagenic and neutralizingantibody studies have suggested that specific regions of both the gpl20 and gp4l glycoproteins are important for postreceptor binding steps involved in membrane fusion. Amino acid changes in the second (V2) and third (V3) variable loops of the gpl2O glycoprotein, which serve as targets for neutralizing antibodies, as well as in the fourth conserved (C4) region of the gp120 glycoprotein, can decrease fusion potential without disrupting receptor binding (7, 21, 26, 34, 47, (59) (60) (61) .
Mutagenic studies have also defined functional regions on the gp4l transmembrane glycoprotein, which contains an external domain, a transmembrane region, and an intracyto-plasmic tail. The external domain is involved in oligomerization, association with the gpl20 glycoprotein, and membrane fusion (10, 15, 16, 20, 36) . The transmembrane domain mainly serves to anchor the viral glycoproteins in the viral or cell membranes, although some alterations in the transmembrane region can affect the fusion function (22, 31) . The intracytoplasmic gp4l domain plays a role in HIV-1 entry other than receptor binding or fusion (14, 23) .
Among the gp4l regions implicated in fusion activity, a discrete stretch of hydrophobic amino acids, referred to as the fusion peptide, is located at the amino terminus of the glycoprotein (24) . Proper cleavage of the gpl60 glycoprotein precursor frees the gp4l fusion peptide from gpl2O sequences and is a prerequisite for fusion functions (40) . Genetic evidence supports the hypothesis that the HIV-1 gp4l fusion peptide interacts with the target cell during the membrane fusion process (7). The concept that gp4l exposure to the target cell is involved in membrane fusion suggests that conformational changes in the envelope glycoproteins are likely to be necessary to effect exposure of gp4l regions buried on the native glycoprotein complex. Such conformational changes could be triggered by CD4 binding. It has been observed that a soluble form of CD4 induces shedding of the HIV-1 gpl20 glycoprotein (3, 5, 9, 28, 43, 44, 53) , leading to exposure of previously hidden gp4l epitopes (56 in both CD4-positive and CD4-negative cells. Here we reexamine the structural and functional properties of glycoprotein products derived from similar or identical constructs.
Expression of a deleted HIV-1 envelope glycoprotein. A construct designed to express an HIV-1 envelope glycoprotein with a deletion in the gp120 moiety analogous to that described by Perez et al. (49) was made, by using an env gene derived from the HXBc2 strain of HIV-1 (55). After cleavage with Kpnl and BglII, blunt ends were generated with mung bean nuclease prior to ligation and Escherichia coli transformation (Fig. 1) . The resultant plasmid, pSVIIIenvA(42-467), should encode a protein containing the signal peptide and the adjacent 11 amino acids of the gpl20 glycoprotein, the carboxylterminal 44 amino acids of the gp120 glycoprotein, and the entire gp4l sequence. A negative control plasmid containing a frameshift mutation at the site of the deletion (pSVIIIFS) was also generated. Plasmids designed to express the wild-type and the deletion-containing envelope glycoproteins (referred to herein as deleted glycoproteins) under the control of the cytomegalovirus immediate-early promoter were also constructed [pCMVenv and pCMVenvA ]. All the plasmids were sequenced to ensure that the env reading frame was preserved at the site of the deletion.
COS-1 cells were transfected by the DEAE-dextran method (12a) with the plasmids expressing either the wild-type or the deleted envelope glycoproteins and with the control plasmid containing the frameshift mutation. At 48 h after transfection, cells were labeled overnight with [35S]cysteine and [35S]methionine. The cells were then lysed in buffer containing 500 mM NaCl, 10 mM Tris [pH 7.5], and 0.5% Nonidet P-40. Cell lysates were precipitated with anti-gp4l monoclonal antibodies [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] and 98-6 (25, 50, 67) . The monoclonal antibody 50-69 recognized both gp160 and gp41 glycoproteins in the lysates of cells transfected with the plasmid expressing the wild-type envelope glycoproteins (Fig. 2, lane 2) . The 50-69 antibody precipitated a 50-to 52-kDa protein from cells transfected with the pSVIIIenvl(42-467) plasmid (Fig. 2, lane 3 Processing of the deleted envelope glycoproteins. The lack of detectable cell fusion activity by the deleted envelope glycoproteins prompted a further characterization of these proteins. Radiolabeled lysates from COS-1 cells transfected with pSVIII-FS, pSVIIIenv, or pSVIIIenvA(42-467) plasmids were precipitated either with the 50-69 monoclonal antibody, which recognizes the gp4l ectodomain, or a polyclonal rabbit antiserum raised against a peptide corresponding to the carboxylterminal (C5) portion of the gpl20 glycoprotein (4). Labeling and immunoprecipitation were carried out as described above. Figure 3 demonstrates that, as expected, the anti-C5 serum precipitated both the gpl60 and the gpl20 glycoproteins, but not the gp4l glycoprotein, from lysates derived from cells transfected with the pSVIIIenv plasmid (lane 5). The rabbit anti-C5 also recognized the 50-to 52-kDa precursor protein encoded by the pSVIIIenvA(42-467) plasmid, as expected (Fig. 3, lane 6) . Unexpectedly, the rabbit anti-C5 serum precipitated both the 39-kDa protein and a less abundant 37-kDa species from pSVIIIenvA(42-467)-transfected cell lysates (Fig. 3, lane 6) . A 42-kDa background band was also precipitated by the anti-C5 serum. Identical results were obtained with the ptrENV plasmid, obtained from Lautaro Perez (data not shown). These results indicate that the deleted precursor molecules encoded by these plasmids are not properly cleaved at the authentic gpl2O-gp4l cleavage site, since all gp4l-related products also contain gpl20 sequences.
Testing the cell-fusing ability of gp4l after gpl2O shedding. Experiments were designed to analyze whether the wild-type gp4l glycoprotein, after removal of the gpl20 glycoprotein, would be able to mediate fusion with SupTl target lymphocytes. Soluble CD4 has been shown to induce the shedding of the HIV-1 gpl20 glycoprotein from the cell membrane envelope glycoprotein complex (28, 43) . Treatment of cells expressing the HIV-1 envelope glycoproteins with soluble CD4 has been demonstrated to expose gp4l epitopes presumably masked by the gpl20 glycoprotein (53a, 56) . Evaluating the fusogenic potential of the soluble-CD4-exposed gp4l glycoprotein by using the wild-type HIV-1 envelope glycoproteins is complicated by the cell-fusing ability of the nondissociated envelope glycoprotein complexes. Instead, mutant HIV-1 envelope glycoproteins, AV3 and 314 G/Q, containing a deletion and a substitution, respectively, in the third variable (V3) region of the gpl20 moiety were used (60, 66) . These mutants are properly processed, are expressed on the cell surface, and efficiently shed the gpl20 glycoprotein in response to soluble CD4 (60, 66 ), yet they are fusion defective. COS-1 cells were transfected with plasmids expressing the wild-type, 314 G/Q, and AV3 envelope glycoproteins or with control plasmids that do not express HIV-1 envelope glycoproteins. At (49) identified these faster-migrating species as the authentic gp4l glycoprotein. Our ability to precipitate these products with antiserum specific for the gpl20 carboxyl terminus rules out the possibility that these represent mature gp4l glycoproteins. Since the exposure of the HIV-1 gp4l amino terminus is likely to be essential for membrane fusion, the ability of such improperly cleaved molecules to mediate fusion would be very unexpected. Indeed, in neither of the syncytium formation assays employed in this study could we detect any cell-fusing ability for either set of constructs designed to express gpl20-deleted HIV-1 envelope glycoproteins.
We also examined whether the wild-type HIV-1 gp4l glycoprotein exposed by soluble-CD4-induced gpl20 shedding might exhibit cell fusion activity. Using conditions previously demonstrated to expose masked gp4l epitopes on the cell surface, we did not observe any cell fusion attributable to the gp4l glycoprotein. These results are consistent with those of another study demonstrating that HIV-1 virions stripped of the gpl20 glycoprotein by soluble CD4 were irreversibly inactivated for the ability to enter target cells (63) . These negative results cannot conclusively prove that the HIV-1 gp4l glycoprotein is incapable of mediating fusion in the absence of the gpl20 exterior glycoprotein. Nonetheless, in conjunction with our inability to reproduce the findings of Perez et al. (49) , the results indicate that evidence for a gpl2O-independent membrane fusion activity for the gp4l glycoprotein is currently lacking. That amino acid changes in multiple gpl2O and gp4l regions affect post-receptor binding events involved in virus entry or cell fusion favors a model in which both HIV-1 envelope glycoproteins are essential for these processes.
For some enveloped viruses, glycoproteins implicated in membrane fusion are encoded by a gene separate from that which encodes the receptor-binding glycoprotein. For example, paramyxovirus fusion proteins expressed independently of other viral glycoproteins are properly processed and transported to the cell surface. The functional activity exhibited by these fusion proteins is typically lower than that observed when a full complement of envelope glycoproteins is present. In some cases, no cell fusion activity was observed unless the homologous receptor-binding glycoprotein was coexpressed with the fusion protein (1, 19, 32, 33, 45, 48, 64) . Thus, even for viral envelope glycoproteins naturally expressed, processed, and transported as independent units, specific interprotein interactions appear to promote efficient function. Such interactions are likely to be even more critical for the function of envelope glycoproteins, like those of HIV-1, that are processed from a single precursor and exist as stable heterodimeric complexes. 
